These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
834 related articles for article (PubMed ID: 29482649)
1. A randomized phase 3 trial comparing paclitaxel plus 5-fluorouracil versus cisplatin plus 5-fluorouracil in Chemoradiotherapy for locally advanced esophageal carcinoma-the ESO-shanghai 1 trial protocol. Chen Y; Zhu Z; Zhao W; Li L; Ye J; Wu C; Tang H; Lin Q; Li J; Xia Y; Li Y; Zhou J; Zhao K Radiat Oncol; 2018 Feb; 13(1):33. PubMed ID: 29482649 [TBL] [Abstract][Full Text] [Related]
2. Comparing Paclitaxel Plus Fluorouracil Versus Cisplatin Plus Fluorouracil in Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Cancer: A Randomized, Multicenter, Phase III Clinical Trial. Chen Y; Ye J; Zhu Z; Zhao W; Zhou J; Wu C; Tang H; Fan M; Li L; Lin Q; Xia Y; Li Y; Li J; Jia H; Lu S; Zhang Z; Zhao K J Clin Oncol; 2019 Jul; 37(20):1695-1703. PubMed ID: 30920880 [TBL] [Abstract][Full Text] [Related]
3. Comparison of paclitaxel in combination with cisplatin (TP), carboplatin (TC) or fluorouracil (TF) concurrent with radiotherapy for patients with local advanced oesophageal squamous cell carcinoma: a three-arm phase III randomized trial (ESO-Shanghai 2). Ai D; Chen Y; Liu Q; Zhang J; Deng J; Zhu H; Ren W; Zheng X; Li Y; Wei S; Ye J; Zhou J; Lin Q; Luo H; Cao J; Li J; Huang G; Wu K; Fan M; Yang H; Zhu Z; Zhao W; Li L; Fan J; Badakhshi H; Zhao K BMJ Open; 2018 Oct; 8(10):e020785. PubMed ID: 30344165 [TBL] [Abstract][Full Text] [Related]
4. A phase II study of concurrent chemoradiotherapy combined with a weekly paclitaxel and 5-fluorouracil regimen to treat patients with advanced oesophageal carcinoma. Xia Y; Li YH; Chen Y; Zhang JH; Liu Q; Deng JY; Ai TS; Zhu HT; Fan JH; Badakhshi H; Zhao KL Radiat Oncol; 2017 Mar; 12(1):47. PubMed ID: 28270162 [TBL] [Abstract][Full Text] [Related]
5. Comparison of 3 Paclitaxel-Based Chemoradiotherapy Regimens for Patients With Locally Advanced Esophageal Squamous Cell Cancer: A Randomized Clinical Trial. Ai D; Ye J; Wei S; Li Y; Luo H; Cao J; Zhu Z; Zhao W; Lin Q; Yang H; Zheng X; Zhou J; Huang G; Li L; Li J; Zhang Z; Zhou G; Gu D; Du M; Mo M; Jia H; Zhang Z; Zhao K JAMA Netw Open; 2022 Feb; 5(2):e220120. PubMed ID: 35188552 [TBL] [Abstract][Full Text] [Related]
6. A prospective, multicenter phase I/II study of induction chemotherapy with docetaxel, cisplatin and fluorouracil (DCF) followed by chemoradiotherapy in patients with unresectable locally advanced esophageal carcinoma. Satake H; Tahara M; Mochizuki S; Kato K; Hara H; Yokota T; Kiyota N; Kii T; Chin K; Zenda S; Kojima T; Bando H; Yamazaki T; Iwasa S; Honma Y; Hamauchi S; Tsushima T; Ohtsu A Cancer Chemother Pharmacol; 2016 Jul; 78(1):91-9. PubMed ID: 27193097 [TBL] [Abstract][Full Text] [Related]
7. Comparison of cisplatinum/paclitaxel with cisplatinum/5-fluorouracil as first-line therapy for nonsurgical locally advanced esophageal squamous cell carcinoma patients. Hu G; Wang Z; Wang Y; Zhang Q; Tang N; Guo J; Liu L; Han X Drug Des Devel Ther; 2016; 10():2129-36. PubMed ID: 27445460 [TBL] [Abstract][Full Text] [Related]
8. Comparison of efficacy and toxicity profiles between paclitaxel/lobapoatin- and cisplatin/5-fluorouracil-based concurrent chemoradiotherapy of advanced inoperable oesophageal cancer. Yang JS; Wang T; Qiu MQ; Li QL Intern Med J; 2015 Jul; 45(7):757-61. PubMed ID: 25851492 [TBL] [Abstract][Full Text] [Related]
9. Long-term results of paclitaxel plus cisplatin with concurrent radiotherapy for loco-regional esophageal squamous cell carcinoma. Zhu HT; Ai DS; Tang HR; Badakhshi H; Fan JH; Deng JY; Zhang JH; Chen Y; Zhang Z; Xia Y; Guo XM; Jiang GL; Zhao KL World J Gastroenterol; 2017 Jan; 23(3):540-546. PubMed ID: 28210091 [TBL] [Abstract][Full Text] [Related]
10. Induction chemotherapy with lobaplatin and fluorouracil versus cisplatin and fluorouracil followed by chemoradiotherapy in patients with stage III-IVB nasopharyngeal carcinoma: an open-label, non-inferiority, randomised, controlled, phase 3 trial. Lv X; Cao X; Xia WX; Liu KY; Qiang MY; Guo L; Qian CN; Cao KJ; Mo HY; Li XM; Li ZH; Han F; He YX; Liu YM; Wu SX; Bai YR; Ke LR; Qiu WZ; Liang H; Liu GY; Miao JJ; Li WZ; Lv SH; Chen X; Zhao C; Xiang YQ; Guo X Lancet Oncol; 2021 May; 22(5):716-726. PubMed ID: 33857411 [TBL] [Abstract][Full Text] [Related]
11. Phase II feasibility study of preoperative concurrent chemoradiotherapy with cisplatin plus 5-fluorouracil and elective lymph node irradiation for clinical stage II/III esophageal squamous cell carcinoma. Hashimoto J; Kato K; Ito Y; Kojima T; Akimoto T; Daiko H; Hamamoto Y; Matsushita H; Katano S; Hara H; Tanaka Y; Saito Y; Nagashima K; Igaki H Int J Clin Oncol; 2019 Jan; 24(1):60-67. PubMed ID: 30109544 [TBL] [Abstract][Full Text] [Related]
12. Concurrent cisplatin and 5-fluorouracil versus concurrent cisplatin and docetaxel with radiotherapy for esophageal squamous cell carcinoma: a propensity score-matched analysis. Zhang P; Xi M; Li QQ; Hu YH; Guo X; Zhao L; Liu H; Liu SL; Luo LL; Liu Q; Liu MZ Oncotarget; 2016 Jul; 7(28):44686-44694. PubMed ID: 27183916 [TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant chemoradiotherapy with concurrent cisplatin/5-fluorouracil is associated with increased pathologic complete response and improved survival compared to carboplatin/paclitaxel in patients with locally advanced esophageal cancer. Haisley KR; Hart KD; Nabavizadeh N; Bensch KG; Vaccaro GM; Thomas CR; Schipper PH; Hunter JG; Dolan JP Dis Esophagus; 2017 Jul; 30(7):1-7. PubMed ID: 28475724 [TBL] [Abstract][Full Text] [Related]
14. Definitive concurrent chemoradiotherapy with docetaxel plus cisplatin versus 5-fluorouracil plus cisplatin in patients with esophageal squamous cell carcinoma: long-term follow-up results of a phase II randomized controlled trial. Jiang H; Makelike K; Chen B; Xi M; Li Q; Hu Y; Zhu Y Radiat Oncol; 2023 Sep; 18(1):150. PubMed ID: 37700348 [TBL] [Abstract][Full Text] [Related]
15. TENERGY: multicenter phase II study of Atezolizumab monotherapy following definitive Chemoradiotherapy with 5-FU plus Cisplatin in patients with unresectable locally advanced esophageal squamous cell carcinoma. Bando H; Kotani D; Tsushima T; Hara H; Kadowaki S; Kato K; Chin K; Yamaguchi K; Kageyama SI; Hojo H; Nakamura M; Tachibana H; Wakabayashi M; Fukutani M; Togashi Y; Fuse N; Nishikawa H; Kojima T BMC Cancer; 2020 Apr; 20(1):336. PubMed ID: 32312286 [TBL] [Abstract][Full Text] [Related]
16. Randomised phase III trial of concurrent chemoradiotherapy with extended nodal irradiation and erlotinib in patients with inoperable oesophageal squamous cell cancer. Wu SX; Wang LH; Luo HL; Xie CY; Zhang XB; Hu W; Zheng AP; Li DJ; Zhang HY; Xie CH; Lian XL; Du DX; Chen M; Bian XH; Tan BX; Jiang H; Zhang HB; Wang JH; Jing Z; Xia B; Zhang N; Zhang P; Li WF; Zhao FJ; Tian ZF; Liu H; Huang KW; Hu J; Xie RF; Du L; Li G Eur J Cancer; 2018 Apr; 93():99-107. PubMed ID: 29494818 [TBL] [Abstract][Full Text] [Related]
17. [Phase II clinical trial of concurrent chemoradiotherapy (cisplatin plus 5-fluorouracil) for esophageal cancer]. Lin Q; Gao XS; Qiao XY; Chen K; Wang YD; Zhou ZG Ai Zheng; 2008 Oct; 27(10):1077-81. PubMed ID: 18851788 [TBL] [Abstract][Full Text] [Related]
18. A Phase II Study of Concurrent Chemoradiotherapy With Paclitaxel and Cisplatin for Inoperable Esophageal Squamous Cell Carcinoma. Tang HR; Ma HF; An SM; Badakhshi H; Deng JY; Zhang JH; Chen Y; Zhang Z; Guo XM; Jiang GL; Zhao KL Am J Clin Oncol; 2016 Aug; 39(4):350-4. PubMed ID: 24732811 [TBL] [Abstract][Full Text] [Related]
19. Long-term results of concurrent chemoradiotherapy with daily-low-dose continuous infusion of 5-fluorouracil and cisplatin (LDFP) for Stage I-II esophageal carcinoma. Kumabe A; Fukada J; Kota R; Koike N; Shiraishi Y; Seki S; Yoshida K; Kitagawa Y; Shigematsu N Dis Esophagus; 2018 Apr; 31(4):. PubMed ID: 29228166 [TBL] [Abstract][Full Text] [Related]
20. Tolerability and efficacy of concurrent chemoradiotherapy comparing carboplatin/paclitaxel versus platinum/5-FU regimen for locally advanced esophageal and esophagogastric junction cancers. Tamtai A; Jiarpinitnun C; Hiranyatheb P; Unwanatham N; Sirachainun E; Supsamutchai C; Pattaranutaporn P; Ngamphaiboon N Med Oncol; 2017 Sep; 34(9):157. PubMed ID: 28785986 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]